(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Ocugen's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast OCGN's revenue for 2025 to be $10,342,178,139, with the lowest OCGN revenue forecast at $10,342,178,139, and the highest OCGN revenue forecast at $10,342,178,139. On average, 1 Wall Street analysts forecast OCGN's revenue for 2026 to be $5,276,255,067, with the lowest OCGN revenue forecast at $5,276,255,067, and the highest OCGN revenue forecast at $5,276,255,067.
In 2027, OCGN is forecast to generate $21,830,922,158 in revenue, with the lowest revenue forecast at $21,830,922,158 and the highest revenue forecast at $21,830,922,158.